MCID: RCT036
MIFTS: 52

Rectal Benign Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Rectal Benign Neoplasm

MalaCards integrated aliases for Rectal Benign Neoplasm:

Name: Rectal Benign Neoplasm 11 14
Primary Malignant Neoplasm of Rectum 33
Neoplasm of the Rectum 5
Primary Rectal Cancer 33
Rectal Ampulla Cancer 33
Cancer of the Rectum 33
Carcinoma of Rectum 33
Neoplasm of Rectum 11
Rectal Carcinoma 33
Rectal Neoplasms 43
Rectum Neoplasm 11
Rectal Cancer 33
Rectal Tumor 11

Classifications:



External Ids:

Disease Ontology 11 DOID:1984
MeSH 43 D012004
NCIt 49 C3350
SNOMED-CT 68 126847008
UMLS 71 C0034885

Summaries for Rectal Benign Neoplasm

MalaCards based summary: Rectal Benign Neoplasm, also known as primary malignant neoplasm of rectum, is related to rectosigmoid junction neoplasm and familial colorectal cancer. An important gene associated with Rectal Benign Neoplasm is MSH2 (MutS Homolog 2), and among its related pathways/superpathways are TCR Signaling (Qiagen) and Endometrial cancer. The drugs Tramadol and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include lymph node, colon and liver, and related phenotype is neoplasm.

Related Diseases for Rectal Benign Neoplasm

Diseases related to Rectal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1072)
# Related Disease Score Top Affiliating Genes
1 rectosigmoid junction neoplasm 32.2 MLH1 KRAS CEACAM5
2 familial colorectal cancer 32.0 TP53 MSH2 MLH1
3 appendix adenocarcinoma 31.0 TP53 MSH6 KRAS HRAS CEACAM5
4 anus cancer 30.8 TP53 KRAS HRAS CEACAM5 CAGE1
5 familial adenomatous polyposis 30.8 TP53 MSH6 MSH2 MLH1 KRAS HRAS
6 mucinous adenocarcinoma 30.7 TP53 MSH6 MSH2 MLH1 KRAS HRAS
7 peripheral nervous system disease 30.7 TP53 MIR31 MIR17 MIR145 MIR143 KRAS
8 lynch syndrome 1 30.7 MSH6 MSH2 MLH1
9 rectosigmoid cancer 30.7 MSH6 MSH2 MLH1 KRAS HRAS CEACAM5
10 mismatch repair cancer syndrome 1 30.7 MSH6 MSH2 MLH1
11 lung benign neoplasm 30.5 TP53 KRAS HRAS
12 diffuse gastric cancer 30.5 TP53 MSH6 MSH2 MLH1 KRAS
13 rectum cancer 30.4 TP53 RAB11B MSH6 MSH2 MLH1 MIRLET7A1
14 lynch syndrome 30.3 TP53 MSH6 MSH2 MLH1 MIR31 MIR17
15 adenosquamous carcinoma 30.3 KRAS HRAS CEACAM5
16 anus disease 30.3 TP53 KRAS HRAS CEACAM5 CAGE1
17 pseudomyxoma peritonei 30.3 TP53 KRAS CEACAM5
18 cholangitis, primary sclerosing 30.3 TP53 KRAS HRAS CEACAM5
19 vulva cancer 30.2 TP53 HRAS CEACAM5
20 gastrointestinal system disease 30.2 MIRLET7A1 MIR99A MIR31 MIR20A MIR17 MIR145
21 transverse colon cancer 30.2 MLH1 KRAS HRAS CEACAM5
22 signet ring cell adenocarcinoma 30.2 TP53 MSH6 MSH2 MLH1 KRAS HRAS
23 cervical cancer 30.2 TP53 MIR31 MIR20A MIR17 MIR143 HRAS
24 intrahepatic cholangiocarcinoma 30.2 TP53 MIR17 KRAS HRAS CEACAM5
25 myoma 30.2 TP53 KRAS CEACAM5
26 desmoid tumor 30.2 TP53 MSH6 MSH2
27 nasopharyngeal carcinoma 30.2 TP53 MIR99A MIR31 MIR17 MIR145 MIR143
28 body mass index quantitative trait locus 11 30.1 TP53 MIRLET7A1 MIR99A MIR20A MIR17 MIR143
29 endometriosis 30.1 TP53 MIR99A MIR20A MIR17 MIR145 MIR143
30 carcinosarcoma 30.1 TP53 KRAS HRAS
31 myeloma, multiple 30.1 TP53 MIR17 MIR145 KRAS HRAS
32 lung large cell carcinoma 30.0 TP53 KRAS HRAS
33 inherited cancer-predisposing syndrome 30.0 TP53 MSH6 MSH2 MLH1
34 bap1 tumor predisposition syndrome 30.0 TP53 MSH6 MSH2 MLH1
35 adenocarcinoma in situ 30.0 TP53 KRAS HRAS CEACAM5
36 mismatch repair cancer syndrome 30.0 TP53 MSH6 MSH2 MLH1 KRAS HRAS
37 suppression of tumorigenicity 12 29.9 TP53 MIR145 HRAS
38 diffuse large b-cell lymphoma 29.9 MIR99A MIR17 MIR145 MIR143
39 breast adenocarcinoma 29.9 TP53 KRAS HRAS CEACAM5
40 microinvasive gastric cancer 29.9 TP53 MLH1 MIR20A CEACAM5
41 adenoma 29.9 TP53 MSH6 MSH2 MLH1 KRAS HRAS
42 cervical squamous cell carcinoma 29.9 TP53 MLH1 KRAS CEACAM5
43 larynx cancer 29.9 TP53 MIR31 MIR17 MIR145 MIR143
44 lymphoma, non-hodgkin, familial 29.9 TP53 MSH2 MIR31 MIR20A MIR17 MIR145
45 arteries, anomalies of 29.9 MIRLET7A1 MIR20A MIR17 MIR145 MIR143
46 gastrointestinal stromal tumor 29.9 TP53 KRAS HRAS CEACAM5
47 bladder cancer 29.8 TP53 MSH2 MLH1 MIR99A MIR31 MIR17
48 adenocarcinoma 29.8 TP53 MSH6 MSH2 MLH1 KRAS HRAS
49 kidney cancer 29.8 TP53 MIR20A MIR17 MIR145
50 rectal disease 29.8 TP53 KRAS HRAS CEACAM5 CAGE1

Graphical network of the top 20 diseases related to Rectal Benign Neoplasm:



Diseases related to Rectal Benign Neoplasm

Symptoms & Phenotypes for Rectal Benign Neoplasm

MGI Mouse Phenotypes related to Rectal Benign Neoplasm:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 CEACAM5 HRAS KRAS MIR31 MLH1 MSH2

Drugs & Therapeutics for Rectal Benign Neoplasm

Drugs for Rectal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 460)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
4
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
7
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
8
Orphenadrine Approved Phase 4 83-98-7 4601
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Iron Approved Phase 4 7439-89-6 29936
11
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
12
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
13
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
14
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523 135413547
15
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
17
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
18
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
19
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
20
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
21
Framycetin Approved, Experimental, Vet_approved Phase 4 1404-04-2, 119-04-0, 3947-65-7 413349 8378
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
23 Anticonvulsants Phase 4
24 Cytochrome P-450 Enzyme Inhibitors Phase 4
25 Parasympatholytics Phase 4
26 Acetaminophen, hydrocodone drug combination Phase 4
27
Ketorolac Tromethamine Phase 4
28 Antiparkinson Agents Phase 4
29 Excitatory Amino Acid Antagonists Phase 4
30 Anesthetics, Dissociative Phase 4
31 Antitussive Agents Phase 4
32 Muscarinic Antagonists Phase 4
33 Cholinergic Antagonists Phase 4
34 Ferric Oxide, Saccharated Phase 4
35 Iron Supplement Phase 4
36 Narcotics Phase 4
37 Phosphodiesterase 5 Inhibitors Phase 4
38 Citrate Phase 4
39 Adrenergic alpha-Agonists Phase 4
40 Adrenergic Agonists Phase 4
41 Anesthetics Phase 4
42 Anesthetics, Intravenous Phase 4
43 Anesthetics, Inhalation Phase 4
44 Anesthetics, General Phase 4
45 Anesthetics, Local Phase 4
46 Antibiotics, Antitubercular Phase 4
47
Cobalt Approved, Experimental, Withdrawn Phase 3 7440-48-4 104729
48
Etodolac Approved, Investigational, Vet_approved Phase 3 41340-25-4 3308
49
Propranolol Approved, Investigational Phase 3 318-98-9, 525-66-6 62882 4946
50
Lanreotide Approved Phase 3 108736-35-2 71349 6918011

Interventional clinical trials:

(show top 50) (show all 1533)
# Name Status NCT ID Phase Drugs
1 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
2 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
3 Konzentrationen Von Ertapenem in Kolorektalem Gewebe Completed NCT00535652 Phase 4 Ertapenem
4 Compression Anastomosis: Initial Clinical Experience With the ColonRingTM Completed NCT01056913 Phase 4
5 A Non-randomised Controlled Trial of Early Intervention to Preserve Erectile Function After Laparoscopic Resection for Rectal Cancer Completed NCT01912586 Phase 4
6 The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer Completed NCT01421940 Phase 4 Placebo drug;Udenafil
7 Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer Completed NCT01579721 Phase 4
8 Assessment of the Effect of Dexmedetomidine in the Management of Postoperative Pain When Combined With Fentanyl in the Patient-controlled Analgesia Completed NCT01373021 Phase 4 Fentanyl;Dexmedetomidine
9 Low-dose Neuroleptanalgesia Reduce the Occurrences of Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Major Surgery : a Randomized Controlled Trial Recruiting NCT05068180 Phase 4 low-dose neuroleptanalgesia;Placebo
10 A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer Recruiting NCT01975064 Phase 4 Propofol;Sevoflurane
11 Total Neoadjuvant Therapy in Rectal Cancer Treatment Recruiting NCT04747951 Phase 4 consolidation chemotherapy;adjuvant chemotherapy
12 Neoadjuvant Chemoradiation With Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer: A Real-Word Multi-center Study Recruiting NCT05148767 Phase 4 Neoadjuvant chemoradiotherapy based on irinotecan
13 Spinal Analgesia for Laparoscopic Abdominoperineal Rectal Amputation Using an Enhanced Recovery After Surgery Program: a Randomized Double-blind Placebo-controlled Trial Recruiting NCT05406765 Phase 4 Bupivacaine Injection
14 Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery - a Prospective, Randomized Controlled Trial Active, not recruiting NCT04281667 Phase 4 Oral Antibiotics;Placebo;Mechanical Bowel Preparation
15 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Suspended NCT01023984 Phase 4
16 Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series Terminated NCT01706822 Phase 4
17 Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer Unknown status NCT00597311 Phase 3
18 5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer Unknown status NCT00189657 Phase 3
19 RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
20 Anastomotic Leakage in Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer : A Prospective, Randomized, Controlled Study Unknown status NCT02770911 Phase 3
21 Resource-Sparing Curative Treatment for Rectal Cancer Unknown status NCT01459328 Phase 3
22 The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak and Short-term Outcomes in Robotic Colorectal Surgery: A Prospective Randomized Trial Unknown status NCT02598414 Phase 2, Phase 3
23 Nano MRI on 7 Tesla: a Technical Validation Study in Rectal and Breast Cancer Unknown status NCT02751606 Phase 3 ferumoxtran-10
24 Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Rectal Anterior Resection for Rectal Cancer Patients Unknown status NCT01861678 Phase 3
25 Investigation of the Value of ctDNA Analysis in the Diagnosis, Treatment, and Surveillance of Patients With Surgically Resectable Colorectal Cancer Unknown status NCT03038217 Phase 3 Capecitabine +/- Oxaliplatin
26 A Comparison for Laparoscopically Assisted and Open Surgery for Advanced Rectal Cancer After Preoperative Chemoradiation- Randomized Prospective Trial Unknown status NCT00470951 Phase 3
27 Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study Unknown status NCT00833131 Phase 3
28 The Randomised Study of Preoperative Radiotherapy and Local Excision for Radiosensitive Rectal Cancer Unknown status NCT00738790 Phase 3
29 A Randomized Phase III Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer Unknown status NCT02605265 Phase 3 Capecitabine;Irinotecan;Oxaliplatin
30 A Randomized Trial Comparing Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer Unknown status NCT00154752 Phase 3
31 INTEnsification Radiotherapy With Accelerated Fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy Unknown status NCT01653301 Phase 3 XELAC RT;XELOX RT
32 Randomized Controlled Trial Comparing the Bladder and Sexual Functions of Patients Who Undergo Laparoscopic and Robotic Assisted Resection for Rectal Cancer Unknown status NCT01130233 Phase 3
33 A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT) Unknown status NCT00601549 Phase 3
34 Randomized Trial of Wide Mesorectal Excision Versus Total Mesorectal Excision for Mid Rectal Cancer Unknown status NCT00007930 Phase 3
35 A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Rectal Cancer. Unknown status NCT00297791 Phase 3
36 (MansTaTME) Trans-anal Versus Laparoscopic Total Mesorectal Excision for Mid and Low Rectal Cancer Unknown status NCT03242187 Phase 2, Phase 3
37 A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
38 An Open Label, Randomized, Multi-center, Phase II/III Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy With Intensity-modified Radiation Therapy (IMRT) in Local Advanced Rectal Cancer Unknown status NCT01064999 Phase 2, Phase 3 Oxaliplatin;Capecitabine
39 A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in Increasing the Pathological Major Response Rate in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy Unknown status NCT01579591 Phase 3
40 Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study Unknown status NCT02907385 Phase 3
41 A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer Unknown status NCT01423214 Phase 3
42 A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer Unknown status NCT01211210 Phase 2, Phase 3 fluorouracil;fluorouracil, oxaliplatin
43 The Safety and Effect of Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer to Prevent Anastomotic Leak: Randomized Control Trial Study Unknown status NCT02905968 Phase 2, Phase 3
44 Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial. Unknown status NCT01814969 Phase 3
45 A Phase III Randomised Study Of J-Pouch Coloanal Anastomosis Versus Side-To-End Coloanal Anastomosis After Preoperative Radiotherapy And Total Mesorectal Excision In Patients With Mid And Distal Rectal Cancer Unknown status NCT00070005 Phase 3
46 Two-Week COurse Versus Conventionally Fractionated Preoperative Chemoradiotherapy In Locally Advanced Rectal Cancer (TwoArc Trial): A Phase III Randomized Clinical Trial Unknown status NCT02484040 Phase 3 Two-week course of radiation
47 Perioperative β-adrenergic Blocker and a COX2 Inhibitor in Patients Undergoing Resection for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Postoperative Immune Perturbations. A Multicenter Randomized Prospective Trial. Unknown status NCT00888797 Phase 3 Propranolol and Etodolac
48 A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy. Unknown status NCT01941979 Phase 3 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
49 A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma Unknown status NCT00337389 Phase 3 5- Fluorouracil (5-FU);bevacizumab (Avastin);Leucovorin;CoFactor (ANX-510)
50 A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma Completed NCT02551237 Phase 3 Capecitabine

Search NIH Clinical Center for Rectal Benign Neoplasm

Cochrane evidence based reviews: rectal neoplasms

Genetic Tests for Rectal Benign Neoplasm

Anatomical Context for Rectal Benign Neoplasm

Organs/tissues related to Rectal Benign Neoplasm:

MalaCards : Lymph Node, Colon, Liver, T Cells, Prostate, Lung, Bone Marrow

Publications for Rectal Benign Neoplasm

Articles related to Rectal Benign Neoplasm:

(show top 50) (show all 31298)
# Title Authors PMID Year
1
Incidental findings on staging CT for rectal cancer: Frequency, clinical significance and outcomes. 62
36356382 2023
2
Impact of endorectal filling on interobserver variability of MRI based rectal primary tumor delineation. 62
36299279 2023
3
BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial. 62
36407490 2023
4
Assessing the Association Between Endoscopic Tattooing and Lymph Node Yield in Rectal Cancer. 62
36115147 2023
5
MRI-based radiomics to predict neoadjuvant chemoradiotherapy outcomes in locally advanced rectal cancer: A multicenter study. 62
36471751 2023
6
Standard versus longer interval of radical resection after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A 20-year single-center experience & propensity-score matching. 62
36169163 2023
7
The Effectiveness of a Self-management Program of Bowel Dysfunction in Patients With Mid and Low Rectal Cancer After Sphincter-Preserving Surgery: A Pilot Randomized Controlled Trial. 62
35089874 2023
8
Primary Colorectal Cancer. 62
36410915 2023
9
Assessing the role of robotic proctectomy in obese patients: a contemporary NSQIP analysis. 62
35147841 2022
10
Interischial Spine Distance Is a Simple Index of the Narrow Pelvis That Can Predict Difficulty During Laparoscopic Low Anterior Resection. 62
36223301 2022
11
Current trends in nonoperative management for rectal adenocarcinoma: An unequal playing field? 62
36056914 2022
12
Magnetic resonance imaging pelvimetry predicts the technical difficulty of rectal surgery. 62
34961711 2022
13
Differences in Surgical Outcomes and Quality-of-Life Outcomes in Pelvic Exenteration Between Locally Advanced Versus Locally Recurrent Rectal Cancers. 62
35913831 2022
14
Robotic versus laparoscopic total mesorectal excision for mid-low rectal cancer with difficult anatomical conditions. 62
35168863 2022
15
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). 62
35831229 2022
16
Could the STELLAR Study Change the Rectal Cancer Treatment Algorithm? 62
35930767 2022
17
Risk of recurrence after local resection of T1 rectal cancer: a meta-analysis with meta-regression. 62
35773606 2022
18
Correction to: The awareness of radiologists for the presence of lateral lymph nodes in patients with locally advanced rectal cancer: a single-centre, retrospective cohort study. 62
35771250 2022
19
Current status of total neoadjuvant therapy for locally advanced rectal cancer. 62
34818447 2022
20
Radiology reporting in rectal cancer using MRI: adherence to national template for structured reporting. 62
34866405 2022
21
Outcomes of laparoscopic versus robotic-assisted resection of T4 rectal cancer: propensity score-matched analysis of a national cancer database. 62
36471483 2022
22
A universal cell-free DNA approach for response prediction to preoperative chemoradiation in rectal cancer. 62
36468189 2022
23
Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 62
36471264 2022
24
"Their Whole Lives Are Going To Change": A Photo-Elicitation Study of Rectal Cancer Survivorship. 62
36382839 2022
25
Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review. 62
36464124 2022
26
Staging and Restaging of Rectal Cancer with MRI: A Pictorial Review. 62
36462804 2022
27
Extracellular volume fraction determined by equilibrium contrast-enhanced CT for the prediction of the pathological complete response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. 62
36462046 2022
28
Determination of biomarkers associated with neoadjuvant treatment response focusing on colibactin-producing Escherichia coli in patients with mid or low rectal cancer: a prospective clinical study protocol (MICARE). 62
36460331 2022
29
Chemoradiotherapy in Locally Advanced Rectal Cancer: Surgeon Perspective. 62
35930762 2022
30
Different neoadjuvant therapies for locally advanced rectal cancer: A systematic review and network meta-analysis. 62
36252747 2022
31
The Impact of Postoperative Complications on Short- and Long-Term Health-Related Quality of Life After Total Mesorectal Excision for Rectal Cancer. 62
36210321 2022
32
Tumour-stroma ratio to predict pathological response to neo-adjuvant treatment in rectal cancer. 62
36332556 2022
33
Life After Rectal Cancer Treatment: Time to Turn to the Experts. 62
36382837 2022
34
The "Hands" teaching method applied to the anatomy of the inferior mesenteric artery related to rectal cancer surgery. 62
36450927 2022
35
Predicting tumor deposits in patients with rectal cancer: Using the models of multiple mathematical parameters derived from diffusion-weighted imaging. 62
36347167 2022
36
Correcting rotational error in rectal cancer radiation therapy: Can planning target volume margins be safely reduced? 62
35715996 2022
37
Alteration of Clinical Tumor Characteristics Is Associated with Pathological Regression in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy. 62
36171472 2022
38
Outcomes of Locally Advanced Rectal Cancer Patients Treated with Total Neoadjuvant Treatment: A Meta-Anaysis of Randomized Controlled Trials. 62
36210320 2022
39
Cost of postoperative complications of lower anterior resection for rectal cancer: a nationwide registry study of 15,187 patients. 62
35608708 2022
40
A Deep Learning Model Based on MRI and Clinical Factors Facilitates Noninvasive Evaluation of KRAS Mutation in Rectal Cancer. 62
35587946 2022
41
A Rectal Cancer Surgical Decision Aid Is Not Enough: A Qualitative Study. 62
36037408 2022
42
[Monotherapy with immune checkpoint blockade leads to clinical complete remission in patients with rectal cancer and microsatellite instability]. 62
35951038 2022
43
Unconsolidated Results of Consolidation Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer. 62
35930759 2022
44
Validation of pelvic magnetic resonance imaging as the method of choice to determine the distance to the anal margin in rectal cancer. 62
36064169 2022
45
Prognostic factors of pelvic MRI at the initial workflow in locally advanced rectal cancer: Focus on extra mural venous invasion and tumour deposits. 62
35870953 2022
46
Usefulness of CT scan as part of an institutional protocol for proactive leakage management after low anterior resection for rectal cancer. 62
36002771 2022
47
Total Neoadjuvant Therapy Is a Predictor for Complete Pathological Response in Patients Undergoing Surgery for Rectal Cancer. 62
36224480 2022
48
Comment on: Transanal Total Mesorectal Excision Versus Anterior Total Mesorectal Excision for Rectal Cancer: A Propensity Score-Matched, Population-Based Study in Catalonia, Spain. 62
36102840 2022
49
Robotic vs. laparoscopic intersphincteric resection for low rectal cancer: a case matched study reporting a median of 7-year long-term oncological and functional outcomes. 62
36198884 2022
50
The Role of Preoperative Imaging in the Detection of Lateral Lymph Node Metastases in Rectal Cancer: A Systematic Review and Diagnostic Test Meta-analysis. 62
36102825 2022

Variations for Rectal Benign Neoplasm

ClinVar genetic disease variations for Rectal Benign Neoplasm:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MSH2 NM_000251.3(MSH2):c.1313CTC[1] (p.Pro439del) MICROSAT Likely Pathogenic
90623 rs587779082 GRCh37: 2:47672723-47672725
GRCh38: 2:47445584-47445586

Expression for Rectal Benign Neoplasm

Search GEO for disease gene expression data for Rectal Benign Neoplasm.

Pathways for Rectal Benign Neoplasm

Pathways related to Rectal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.71 HRAS KRAS MLH1 MSH2 MSH6 TP53
2
Show member pathways
12.35 TP53 MSH6 MSH2 MLH1 KRAS HRAS
3 12.34 TP53 MSH6 MSH2 MLH1
4 11.96 KRAS MSH2 MSH6 TP53
5 11.76 TP53 KRAS HRAS
6 11.71 MSH2 MLH1 MIR145
7
Show member pathways
11.63 TP53 MSH6 MSH2
8 11.61 TP53 MSH2 MLH1
9
Show member pathways
11.58 TP53 KRAS HRAS
10 11.57 TP53 MSH6 MSH2 MLH1 KRAS
11 11.53 TP53 KRAS HRAS
12
Show member pathways
11.35 MIR20A MIR17 MIR145 MIR143
13
Show member pathways
11.21 TP53 MSH2 MLH1
14 11.18 TP53 KRAS HRAS
15 11.17 TP53 KRAS HRAS
16 11.12 TP53 MSH6 MSH2
17 10.96 MSH6 MSH2 MLH1
18 10.93 TP53 MIRLET7A1 MIR20A MIR17 MIR145 MIR143
19
Show member pathways
10.63 KRAS HRAS

GO Terms for Rectal Benign Neoplasm

Cellular components related to Rectal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.46 MIRLET7A1 MIR99A MIR20A MIR17
2 RISC complex GO:0016442 9.44 MIRLET7A1 MIR99A MIR31 MIR20A MIR17 MIR145
3 mismatch repair complex GO:0032300 9.43 MSH2 MLH1
4 MutSalpha complex GO:0032301 9.26 MSH6 MSH2

Biological processes related to Rectal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 10.31 MIR143 MIR145 MIR17 MIR20A MIR31 MIR99A
2 intrinsic apoptotic signaling pathway GO:0097193 10 TP53 MSH6 HRAS
3 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.99 MSH6 MSH2 MLH1
4 mismatch repair GO:0006298 9.99 MSH6 MSH2 MLH1
5 determination of adult lifespan GO:0008340 9.93 TP53 MSH6 MSH2
6 isotype switching GO:0045190 9.91 MSH6 MSH2 MLH1
7 positive regulation of helicase activity GO:0051096 9.88 MSH6 MSH2
8 positive regulation of isotype switching to IgA isotypes GO:0048298 9.84 MLH1 MSH2
9 somatic hypermutation of immunoglobulin genes GO:0016446 9.73 MSH6 MSH2 MLH1
10 maintenance of DNA repeat elements GO:0043570 9.72 MSH2 MSH6
11 angiotensin-activated signaling pathway GO:0038166 9.6 MIR145 MIR143
12 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR20A MIR17
13 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.58 MSH2 MLH1
14 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.57 MIRLET7A1 MIR99A
15 aorta smooth muscle tissue morphogenesis GO:0060414 9.56 MIR145 MIR143
16 somatic recombination of immunoglobulin gene segments GO:0016447 9.55 MSH6 MSH2 MLH1
17 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.5 MIR31 MIR20A MIR17
18 regulation of phenotypic switching GO:1900239 9.48 MIR145 MIR143
19 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.37 MIR143 MIR145
20 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.35 MIRLET7A1 MIR31 MIR20A MIR17 MIR145
21 positive regulation of pulmonary blood vessel remodeling GO:1905111 8.8 MIR20A MIR17 MIR143

Molecular functions related to Rectal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein activity GO:0003925 9.91 RAB11B KRAS HRAS
2 ATP-dependent DNA damage sensor activity GO:0140664 9.8 MLH1 MSH2 MSH6
3 MutLalpha complex binding GO:0032405 9.78 MSH6 MSH2
4 oxidized purine DNA binding GO:0032357 9.76 MSH6 MSH2
5 single guanine insertion binding GO:0032142 9.71 MSH6 MSH2
6 mRNA 3'-UTR binding GO:0003730 9.7 TP53 MIR31 MIR20A MIR17 MIR145 MIR143
7 single thymine insertion binding GO:0032143 9.67 MSH6 MSH2
8 mismatched DNA binding GO:0030983 9.65 MSH6 MSH2 MLH1
9 guanine/thymine mispair binding GO:0032137 9.43 MSH6 MSH2 MLH1
10 mRNA base-pairing translational repressor activity GO:1903231 9.17 MIRLET7A1 MIR99A MIR31 MIR20A MIR17 MIR145

Sources for Rectal Benign Neoplasm

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....